key: cord-0865599-vgd1k7wh
authors: Husain, Syed Ali; Argyropoulos, Christos P.
title: Boosters and optimizing SARS‐CoV‐2 vaccine for transplantation: No time to wait
date: 2021-08-23
journal: Am J Transplant
DOI: 10.1111/ajt.16788
sha: 96f2a228c1971679ea8881a658ae8ffd702230ad
doc_id: 865599
cord_uid: vgd1k7wh

We read with appreciation Ison and colleagues' thoughtful perspective regarding optimizing SARS-CoV2 vaccination in solid organ transplant recipients (SOTRs).1 However, we respectfully counter that waiting for clinical trials to guide vaccination strategies is divorced from the reality that SOTRs face in a society with increasingly adversarial attitudes towards masking and social distancing.

To the Editor:

We read with appreciation Ison and colleagues' thoughtful perspective regarding optimizing SARS-CoV-2 vaccination in solid organ transplant recipients (SOTRs). 1 However, we respectfully counter that waiting for clinical trials to guide vaccination strategies is divorced from the reality that SOTRs face in a society with increasingly adversarial attitudes toward masking and social distancing. Despite the proliferation of the SARS-CoV-2 delta variant in the United States, only eight states currently mandate masking for unvaccinated individuals, decreasing the feasibility of SARS-CoV-2 avoidance.

A strategy to wait for additional evidence also disregards that current recommendations themselves lacked empiric evidence.

Based on reasonable inferences, we recommended standard SARS-CoV-2 vaccination to SOTRs as safe and effective despite SOTRs' exclusion from vaccine trials. Similarly, a strategy of empiric vaccine "boosters" should be pursued in the absence of trial data given the reasonable potential for benefit and minimal likelihood of harm, a scenario we believe exists given that:

1. It is likely that vaccine-induced immunity is lower in SOTRs than immunocompetent individuals. Furthermore, boosting using original or modified vaccines will likely be used going forward to achieve protective immunity against emerging variants of concern.

3. It is unlikely that booster doses carry a significant risk of adverse events.

Although the authors quote a sixfold higher incidence of rejection The unfortunate reality is that SARS-CoV-2 avoidance remains challenging as increasingly transmissible variants proliferate. It is imperative that we act urgently to improve transplant recipients' protection. In the absence of a reasonable expectation for harm, vaccine boosters should be pursued even if the potential benefit is uncertain.

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

No data is analyzed in this letter. 

Antibodies, boosters and optimizing SARS-CoV-2 vaccine for transplantation: a call for more research

Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Influenza virus vaccination and kidney graft rejection: causality or coincidence